Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm not giving you the valuable research that I did. One thing for sure is you know little about clinical trials.
Can the BAT change during a trial? Or must these CR2 patients in that arm just live (or rather die) with the old treatments from 2019? Would that be ethical? Would that be a test of BAT if it did?
Correct, my estimate. Those VIALE-A trials on CR1 patients were 3+ years ago. Other trials on CR2 patients were also years ago. The field has moved on since then and knows how to treat patients on ven/aza with additional inhibitors depending on the karyotypes presented. MRD negative status is also a huge helper in addition to patient age.
The doctors on the conference call last January were just giving lip service. Again, are you going to be able to sue them for saying "CR2 patients have a low 5-7 months expected survival"? If BAT MOS was 6 months, you would already have your 60 events. My last estimate has BAT 13 MOS vs GPS 21 MOS (0.619). It's very tight and the fact that Abbvie and Roche are seeing no degradation in stock price (and SLS seeing absolute nothing in stock price) indicates that it is not going to be a white Christmas.
Correct. To pass muster at Final Analysis, they need to be 0.636. So at the last meeting, it is very tight. My estimates show it to be at 0.619.
So in June, at 0.619, you would not get a "halt for futility" or any "futility concerns". You would only get that if the HR number was above 0.636 and you still may not get a "futility halt" if the number was just slightly above 0.636 (say 0.643) at the time they looked at the data. You need to understand that the CEO (and company) is grifting investors.
Let's put it another way, when the trial fails, what "evidence" are you going to use to sue Stergiou and/or the company for lying about the trial? You won't have any because they have covered their bases.
REGAL has failed means that the upcoming readout will be receiving a failing grade. They can't report until the 60th event, but at this point, it is obvious that this trial is DOA. Oncology is hard.
Well, I used to think Sellas was going to be a stock to play. I used to think that it was going to have some decent volatility heading into September that would have nice to swing trade. But now, I will recognize that this stock is a sham. If you just go read the posts on other boards (like Stocktwits), it is like a desperation pump show. Ignore the posters over there like @GPS_vs_SOC and a few others that post all the time. Instead, watch the posters that do post with some regularity continually saying "they bought more shares" or "this is going to rocket soon" or etc, etc, etc...
In all likelihood, GPS REGAL trial has failed. Oncology is a tough business and it is even tough when the CEO is retarded.
Bunion (Hallux Valgus) Treatment Market Size was valued at USD 0.021 Billion in 2022.
Not much trading for me lately. Bought the big ETF's (blue chips, high dividend) on the correction in early August and riding them still. Probably sell and move everything to cash before the election.
Hey gdog, why did the case get transferred from your boy Gilstrap?
LOL, all of the good emoticon reactions were removed. You're welcome, I suppose.
Yep some. Now watch the stock skyrocket.
Sold all SLS. CEO lied and said no dilution until after Interim Analysis which was to be by end of Q3.
When the CEO lies, you move on.
Yes, I'm liking my 200,000 shares long. Binary event is approaching for them.
1. Will their REGAL trial halt for efficacy at 60 events (deaths) Interim Analysis with a hazard ratio of 0.52? Essentially, is the median overall survival (MOS) of their drug extend by double (Ex: 24 months vs 12 months)? If it halts, it is headed to $15 straight away. Currently, no futility or safety concerns with drug reported since the trial started 3 years ago so that is essentially off the table.
2. If they don't get halt for efficacy at 60 events for Interim Analysis, the trial will continue to conclusion at 80 events (deaths) which will likely take the trial until Q1 2025. The need a hazard ratio of 0.62 at Final Analysis to have immediately successful trial results. There are cases were a hazard ratio slightly above that number could still gain approval because the secondary endpoints on toxicity are likely to be met. In short, current best available treatments come with lots of side effects.
3. Shorts will cut the stock to $0.80/share if 60 events does not get halt for efficacy because the company will need to dilute. The only thing that stops dilution before REGAL trial completes (if it has to go to 80 events) would be settlement with 3DMedical which owes them at least $13M minimum or their other drug SLS009 (Phase 2 AML patients with ASX1 mutation showing 100% response rate) gets a partnership deal.
Place your bets.
The park's website says there are some road closures.
https://www.nps.gov/gett/planyourvisit/conditions.htm
Check yourself for ticks.
But as far as a destination, looks interesting especially if you are interested in history.
Is it going to be a sh_t show for Sellas? Or a REG SHO extravagammasqueeze?
No idea. The bottom swing on ALLR was at $0.14 to $0.15/share. Now that it is up 50% from that bottom, it is time to move on. It's not going anywhere. There are many many many many other opportunities in the market. Even daily swing trades on blue chips are a better option.
So you are no longer checking here?
If I am going to retire early, it will be because of SLS. If not, I will end up working for another 20 years.
SLS up approximately 12% since July 18th. $1.10 ----> $1.25
Still holding.
Looks like NAAS trade halted earlier today. Now at $7.33. Seems like you lucked out?
This is Bottom Swing Plays Chat, right? Recent Bottom Swing on SLS was a brief dip to $0.81 (for about 2 minutes) a few weeks back. Didn't get that.
I'm buying SLS now because
1. Phase 3 Regal Trial data imminent for drug GPS.
2. In the last 30 days, their drug SLS009 has received two (2) Priority Review Vouchers for Rare Pediatic Disease Designation (RPDD) because the drug has a 99%+ overall response rate in patients.
3. Commercial team left in March 2024. Company is looking to be bought out and actively seeking such. Abbvie, Merck, Novartis are my guesses for interested parties.
I'm 200,000 shares long right now.
Added SLS again at $1.10 today. Awaiting Phase 3 REGAL trial Interim Analysis (IA) when the 60th event (typically death of patient, relapse of patient).
https://duediligencegenie.com/wp-content/uploads/2024/05/Sellas-Life-Sciences.pdf This should be sticky posted.
Amen
10K. Should have sold in the morning, but rolled the dice.
Sold SLS.
Yes, loving it. Did you get some at the bottom in the first 30 minutes of trading today? I got $0.98.
It might, but the call options aren't in your favor to get back down that far.
Nice little dip of SLS to low 1.5x. 200,000 shares there now.
Don't know what "member marked" is. As far as one of these stocks, I just point out the realities. I find it sad that people park their cash in a company like that while the CEO enriches themselves far, far, far beyond the performance of the company.
Which hits $2 first?
NLST with surprise settlement or 912 invalidation remanded at PTAB.
OR
SLS with Phase 3 data reporting any day for AML drug that performed above expectations in Phase 2.
SLS
SMCI (Super Micro) went from $250 to $750 during NVDA's rally because SMCI supplies NVDA.
So the pump is to attach NLST to SMCI. All without context such as to what extent is SMCI a customer of NLST?
Netlist will be $0.80/share by August 1st, 2024. Downhill from there. We can agree to disagree, remember?
Tell that to Hong.
Attack all you want. I'm just showing you that there are other pieces of information that may be blocked by the rose colored glasses.
It's success, but not winning. It's like getting a 1st down in football. You got one, but the game is not over yet. As stated before, you still have significant risk ahead. The FOMO crowd doesn't want you to think about risk. I suppose if you think there is no risk ahead then that is your prerogative.
Well, we can agree to disagree on how Hong pays himself before meeting the company goals.
Now I'm sure this will get deleted, but the biggest issue on this board is that posts with counter views get deleted. You know it. I know it. Anyone who is a mod knows it. And many who are not mods know it. This is the #1 reason that the 🤡 is in effect.
And as far as being wrong, I would admit it if it ever comes to pass. However, that wouldn't make my viewpoint unreasonable. I think that is a stretch to say my current viewpoint is unreasonable. It's rather reasoned at this time. I'm not here screaming "Hong kills baby kittens!!". I'm here saying things are not nearly as rosy as is being made out to be, and that there is significant risk that should be exposed and/or discussed.
I think I have been pretty clear on my counterpoints.
1. Hong moved to OTC. Then gave himself a 50% raise ($500K --> $750K). Then gave himself more shares. Then continues to sell more shares. Hong NEVER buys shares. Hong just recently gave himself another 750,000 shares.
2. Hong has made over $20M (~$23M) from Netlist. The company is not successful. It doesn't matter why they are not successful, it is still cart before the horse. Hong wants you to be patient? Wait for things to play out? Yet, the same virtue is not actioned by him.
3. Netlist **may** make it. But that is not for 18 months minimum and more like 2+ years. A lot of risks between now and then. '912 patent at the CAFC is not a given as they are going to be ruling on new prior art. HBM patents failed first IPR.
I've been around for a while. Every company I have ever researched with #1 and #2 above from the CEO/President has ended up insolvent. Perhaps Netlist breaks the mold. Odds not in favor.